New hope for HIV patients with lung cancer: immunotherapy combo trial opens

NCT ID NCT04499053

Recruiting now Disease control Sponsor: Georgetown University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding two immunotherapy drugs (durvalumab and tremelimumab) to standard chemotherapy is safe and effective for people with HIV who have advanced non-small cell lung cancer. About 18 participants will receive the treatment, and researchers will monitor side effects, tumor response, and HIV viral load. The goal is to find a better way to control the cancer while managing HIV.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, NON-SMALL-CELL LUNG

Contacts and locations

Locations

Georgetown Lombardi Comprehensive Cancer Center
RECRUITING

Washington D.C., District of Columbia, 20007, United States
Harry and Jeannette Weinberg Cancer Institute at Franklin Square
RECRUITING

Baltimore, Maryland, 21237, United States
Marlene and Stewart Greenebaum Comprehensive Cancer Center
RECRUITING

Baltimore, Maryland, 21201, United States
Medstar Washington Hospital Center
RECRUITING

Washington D.C., District of Columbia, 20010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.